Targeted Therapy Stocks List Ranked for 2024 |

Targeted Therapy ETFs
Recent Targeted Therapy News

Symbol	Grade	Name	% Change
AVTX	C	Avalo Therapeutics, Inc.	0.60
ATRA	C	Atara Biotherapeutics, Inc.	-10.45
CRDF	C	Cardiff Oncology, Inc.	-4.38
APTO	D	Aptose Biosciences, Inc.	1.29
CELC	D	Celcuity Inc.	-3.62
BCAB	D	BioAtla, Inc.	-14.07
IDYA	F	IDEAYA Biosciences, Inc.	-3.35
OLMA	F	Olema Pharmaceuticals, Inc.	-12.02
CLRB	F	Cellectar Biosciences, Inc.	-3.83
POAI	F	Predictive Oncology Inc.	-8.63

View As Page of Charts

Related Industries: Biotechnology Diagnostics & Research Medical Instruments & Supplies

Related ETFs - A few ETFs which own one or more of the above listed Targeted Therapy stocks.

Symbol	Grade	Name	Weight
SBIO	C	ALPS Medical Breakthroughs ETF	2.39
BBC	C	Virtus LifeSci Biotech Clinical Trials ETF	2.1
JFWD	B	Jacob Funds Inc. Jacob Forward ETF	1.89
CNCR	D	Loncar Cancer Immunotherapy ETF	1.08
FORH	D	Formidable ETF	0.98

View all Targeted Therapy ETFs...

Compare ETFs

Compare BBC to JFWD Compare SBIO to CNCR Compare SBIO to FORH

Targeted Therapy Stocks Recent News

Date	Stock	Title
Nov 14	CLRB	Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
Nov 14	CELC	Earnings Scheduled For November 14, 2024
Nov 13	POAI	Predictive Oncology GAAP EPS of -$0.36 misses by $0.10, revenue of $0.35M in-line
Nov 13	POAI	Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Nov 12	OLMA	Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 12	AVTX	Avalo Therapeutics receives $69.4M in proceeds from full exercise of private placement warrants
Nov 12	CLRB	Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Nov 12	CELC	Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
Nov 12	AVTX	Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Nov 12	IDYA	IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
Nov 12	ATRA	Earnings Scheduled For November 12, 2024
Nov 11	CLRB	Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
Nov 11	ATRA	Insights into Atara Biotherapeutics's Upcoming Earnings
Nov 11	AVTX	Avalo Therapeutics to Present at Upcoming Investor Conferences
Nov 11	IDYA	IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
Nov 11	IDYA	Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Nov 9	BCAB	BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
Nov 9	CRDF	Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations
Nov 8	APTO	Aptose Biosciences GAAP EPS of -$0.37 beats by $0.27
Nov 8	BCAB	BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Targeted Therapy: Targeted therapy is a type of cancer treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells. It works by targeting the molecules and pathways that are involved in the growth and spread of cancer cells. Targeted therapy is used to treat many types of cancer, including breast, lung, and colorectal cancer.

Browse All Tags